These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 915733)

  • 1. Evaluation of drug formulations using LD50 testing in mice.
    Sheth PR; Shah NH; Pool W
    J Pharm Sci; 1977 Nov; 66(11):1567-70. PubMed ID: 915733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
    Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
    Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drugs and the organism. II. Bioavailability].
    Pflegel P; Pfeifer S
    Pharmazie; 1980; 34(5-6):337-59. PubMed ID: 6893363
    [No Abstract]   [Full Text] [Related]  

  • 4. Gastrointestinal absorption II. Formulation factors affecting drug bioavailability.
    Blanchard J
    Am J Pharm Sci Support Public Health; 1978; 150(5):132-51. PubMed ID: 364993
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymeric formulations for drug release prepared by hot melt extrusion: application and characterization.
    Stanković M; Frijlink HW; Hinrichs WL
    Drug Discov Today; 2015 Jul; 20(7):812-23. PubMed ID: 25660507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application research of hot-melt extrusion in preparation of solid dispersion].
    Chen MW; Chen WR; Chen TK; Chen RE; Wang YT
    Yao Xue Xue Bao; 2012 Feb; 47(2):163-7. PubMed ID: 22512025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
    Hu L; Tang X; Cui F
    J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependence of Dosage Form Microstructure and Performance.
    Axel Zeitler J; Rades T
    Pharm Res; 2017 May; 34(5):887-889. PubMed ID: 28299534
    [No Abstract]   [Full Text] [Related]  

  • 9. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.
    Kanzer J; Tho I; Flaten GE; Mägerlein M; Hölig P; Fricker G; Brandl M
    J Pharm Pharmacol; 2010 Nov; 62(11):1591-8. PubMed ID: 21039543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process.
    Abuzar SM; Hyun SM; Kim JH; Park HJ; Kim MS; Park JS; Hwang SJ
    Int J Pharm; 2018 Mar; 538(1-2):1-13. PubMed ID: 29278733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical method for preparing nanosuspension formulations for toxicology studies in the discovery stage: formulation optimization and in vitro/in vivo evaluation of nanosized poorly water-soluble compounds.
    Komasaka T; Fujimura H; Tagawa T; Sugiyama A; Kitano Y
    Chem Pharm Bull (Tokyo); 2014; 62(11):1073-82. PubMed ID: 25366311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hot-melt extrusion.
    Jana S; Miloslava R
    Ceska Slov Farm; 2012 Jun; 61(3):87-92. PubMed ID: 22913823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Formulation and special investigations of innovative intraoral solid dosage forms.].
    Kristo K; kATONA B; Piukovics P; Olah I; Sipos B; Sipos SE; Sovany T; Hodi K; Ifi Regdon G
    Acta Pharm Hung; 2016; 86(3):99-111. PubMed ID: 29489081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options.
    Aungst BJ
    J Pharm Sci; 2017 Apr; 106(4):921-929. PubMed ID: 27986598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric formulations: international issues and potential solutions.
    Knoppert DC
    Paediatr Drugs; 2009; 11(1):55-6. PubMed ID: 19127956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a Review.
    Ellenberger DJ; Miller DA; Williams RO
    AAPS PharmSciTech; 2018 Jul; 19(5):1933-1956. PubMed ID: 29846889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
    Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.